Zhe Tang

Dr. Zhe Tang


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2020 in Small
Verified
Journal Article
Closed access
PDF file
YLYangyang Li
Yangyang Li
WCWeiyu Chen
Weiyu Chen
YQYuchen Qi
Yuchen Qi
SWShuai Wang
Shuai Wang
LLLei Li
Lei Li
MZMin Zhou
Min Zhou

1 January 2022 in Theranostics
Verified
Journal Article
Open access
MSMinqi Shi
Minqi Shi
ZDZhen Du
Zhen Du
YQYuchen Qi
Yuchen Qi
WLWanlin Li
Wanlin Li
HHHuiqun Hu
Huiqun Hu
MZMin Zhou
Min Zhou
Rationale: Chronic wounds are one of the common complications of diabetes. Due to the physiological conditions of diabetic patients, these wounds are more susceptible to bacterial infections and the formation of bacterial biofilms, leading to the inefficiency of conventional antibiotic treatment.

15 December 2023 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
LLLei Lei
Lei Lei
WDWenbin Dai
Wenbin Dai
JMJiaping Man
Jiaping Man
HHHaitao Hu
Haitao Hu
QJQiao Jin
Qiao Jin
ZTZhe Tang
Zhe Tang
Phototherapy, including photodynamic therapy (PDT) and photothermal therapy (PTT), has great promise in the treatment of cancer. However, there are many obstacles that can restrict the therapeutic efficacy of phototherapy. The hypoxic tumor microenvironment can restrict the production of reactive oxygen species (ROS) in PDT. As for PTT, the thermotolerance of cancer cells may lead to ineffective PTT. In this study, IR780 and glycolysis inhibitor lonidamine (LND)-encapsulated liposomes are prepared for photodynamic and photothermal therapy of hepatocellular carcinoma. IR780 can be used as a photosensitizer and photothermal agent for simultaneous PDT and PTT after being irradiated with 808 nm laser. LND can reduce the oxygen consumption of cancer cells by inhibiting glycolysis, which will relieve tumor hypoxia and produce more ROS for PDT. On the other hand, energy supply can be blocked by LND-induced glycolysis inhibition, which will inhibit the production of heat shock proteins (HSPs), reduce the thermotolerance of tumor cells, and finally enhance the therapeutic efficacy of PTT. The enhanced PTT is studied by measuring intracellular HSPs, ATP level, and mitochondrial membrane potential. The antitumor effect of IR780 and LND co-loaded liposomes is extensively investigated by in vitro and in vivo experiments. This research provides an innovative strategy to simultaneously enhance the therapeutic efficacy of PDT and PTT by inhibiting glycolysis, which is promising for future creative approaches to cancer phototherapy.

12 October 2022 in Biomaterials
Verified
Journal Article
Closed access
WDWenbin Dai
Wenbin Dai
YDYongyan Deng
Yongyan Deng
XCXiaohui Chen
Xiaohui Chen
YHYue Huang
Yue Huang
HHHaitao Hu
Haitao Hu
JJJian Ji
Jian Ji

8 March 2021 in Frontiers in Genetics
Verified
Journal Article
Open access
PDF file
NLNa Luan
Na Luan
YMYali Mu
Yali Mu
JMJiayi Mu
Jiayi Mu
YCYiquan Chen
Yiquan Chen
XYXun Ye
Xun Ye
JWJianwei Wang
Jianwei Wang
Hypoxia plays a key role in colorectal cancer (CRC) metastasis, but its underlying mechanism remains largely unknown. Dicer1, an RNase, has been considered as a tumor regulator in many tumors. However, whether Dicer1 affects CRC progression under hypoxia remains uncertain. In this study, we found that Dicer1 expression was induced by hypoxia in CRC cells and it mediates hypoxia-induced CRC cell progression. Furthermore, we found that the expression of tRF-20-MEJB5Y13, a small non-coding RNA derived from tRNA, was increased under hypoxic conditions, and its upregulation by Dicer1 resulted in hypoxia-induced CRC cell invasion and migration. These results advance the current understanding of the role of Dicer1 in regulating hypoxia signals and provide a new pathway for the development of therapeutic interventions for inhibiting cancer progression.

1 March 2023 in Nano TransMed
Verified
Journal Article
Open access
PDF file
YLYuting Lu
Yuting Lu
TZTangye Zeng
Tangye Zeng
HZHuamiao Zhang
Huamiao Zhang
YLYang Li
Yang Li
XZXiaoling Zhu
Xiaoling Zhu
LTLongguang Tang
Longguang Tang
Lung cancer has the highest incidence and mortality rate worldwide. Immunotherapy is a universal treatment for lung cancer, but its overall treatment remains a challenge. Tumor immunoediting is a process in which the immune system restricts or promotes tumor development through elimination, equilibrium, and escape to change tumor immunogenicity and obtain an immunosuppressive mechanism to promote disease progression. An increasing number of immunotherapy drugs, including monoclonal antibody-targeting drugs and chimeric antigen (Ag) receptor-modified T cells (CAR-T cells), have been used in clinical therapy. Additionally, cancer vaccine development and new clustered regularly spaced short palindromes (CRISPR)-based combination therapies against cancer open up new avenues for immunotherapy. However, these immunotherapies cause autoimmune induction and non-specific inflammation, with many limitations. The development and study of nanoparticle systems have shown the possibility of localization, pharmacokinetic programming, and immunomodulator co-delivery. Rapid advances in nanotechnology over the past decade have provided a strategic impetus for cancer immunotherapy improvements. Nanotechnology advancements in various aspects, such as virus-like size, high surface–volume ratio, and surface modifications to precisely target specific cell types, can be investigated through cancer vaccine and immunomodulator delivery system development. This review presents the current immunotherapy approaches for lung cancer and emphasizes the current process and prospects of the fusion of cancer immunotherapy, nanotechnology, bioengineering, and drug delivery.